ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Agenus Inc

Agenus Inc (AGEN)

14.07
0.50
( 3.68% )
Updated: 12:47:39

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
14.07
Bid
14.03
Ask
14.10
Volume
248,693
13.33 Day's Range 14.21
4.775 52 Week Range 38.60
Market Cap
Previous Close
13.57
Open
13.57
Last Trade
2
@
14.0725
Last Trade Time
12:48:47
Financial Volume
$ 3,423,784
VWAP
13.7671
Average Volume (3m)
2,628,099
Shares Outstanding
20,999,261
Dividend Yield
-
PE Ratio
-1.21
Earnings Per Share (EPS)
-11.71
Revenue
156.87M
Net Profit
-245.97M

About Agenus Inc

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multip... Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Agenus Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker AGEN. The last closing price for Agenus was $13.57. Over the last year, Agenus shares have traded in a share price range of $ 4.775 to $ 38.60.

Agenus currently has 20,999,261 shares outstanding. The market capitalization of Agenus is $296.72 million. Agenus has a price to earnings ratio (PE ratio) of -1.21.

AGEN Latest News

Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors

Strategic leadership to drive next phase of growth for the company Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to...

Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50

BOT/BAL Combination Shows Promising Results in the Most Prevalent Form of Colorectal Cancer, Affecting 95% of Diagnosed Patients Agenus has published results from a groundbreaking clinical trial...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.64-10.439210693815.7116.7612.3469069513.72779668CS
41.5212.111553784912.5519.68812.3467077015.67699377CS
122.2719.237288135611.819.6884.775262809910.26898483CS
26-1.05-6.9444444444415.1219.6884.775678528013.01679001CS
52-23.33-62.379679144437.438.64.775664759016.72275694CS
156-91.53-86.6761363636105.6135.84.775522784639.7629652CS
260-44.93-76.152542372959135.84.775415715847.95110396CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.7989
(165.42%)
280.45M
SHCRSharecare Inc
$ 1.365
(76.27%)
32.87M
NXLNexalin Technologies Inc
$ 1.8801
(70.92%)
40.72M
SPECSpectaire Holdings Inc
$ 0.5485
(61.32%)
58.76M
MINMMinim Inc
$ 3.8242
(33.71%)
41.49M
KAVLKaival Brands Innovations Group Inc
$ 1.4601
(-49.13%)
3.26M
PBMPsyence Biomedical Ltd
$ 0.4037
(-32.72%)
2.18M
FBLGFibroBiologics Inc
$ 4.18
(-21.87%)
269.24k
RELIReliance Global Group Inc
$ 0.4737
(-21.56%)
7.46M
CRKNCrown Electrokinetics Corporation
$ 0.0402
(-19.60%)
133.89M
NVDANVIDIA Corporation
$ 128.22
(-1.96%)
284.54M
AREBAmerican Rebel Holdings Inc
$ 0.7989
(165.42%)
280.45M
CRKNCrown Electrokinetics Corporation
$ 0.0402
(-19.60%)
133.89M
NKLANikola Corporation
$ 0.3669
(11.32%)
118.34M
ASTIAscent Solar Technologies Inc
$ 0.1089
(0.93%)
112.3M

AGEN Discussion

View Posts
jondoeuk jondoeuk 2 months ago
I expect more dilution is on the way after the R/S. Unless they sell non-strategic assets, which is hardly a sustainable business practice.
👍️0
jondoeuk jondoeuk 3 months ago
The co-founder/CEO/Chairman has been for 20+ years pumping the company, telling stories and making promises, all the while getting rich off retail.
👍️ 1
jondoeuk jondoeuk 3 months ago
They are proposing a R/S at a ratio of 1-for-20 https://finance.yahoo.com/news/why-agenus-stock-plummeted-nearly-233805990.html
👍️0
Paullee Paullee 4 months ago
where did you see that ??????
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
ALL OUT...REVERSE SPLIT ANNOUNCEMENT
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
AGEN SMALL GAPPER AND ON TARGET TO 1.04
👍️0
DP1011 DP1011 4 months ago
Interesting, would be nice to see this back over a dollar.
👍️0
Stumblebum Stumblebum 4 months ago
Something is cooking …..last week good upward movement and picked up volume 😊
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
AGEN POPPING HARD TO 1.04
👍️0
axelvento axelvento 4 months ago
A Biologics License Application (BLA) is expected to be submitted to the FDA for metastatic colorectal cancer (CRC) in mid-2024.

Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor typically unresponsive to IO therapy

Who knows what does the future hold$$$$$$$
👍️0
Denzel-72 Denzel-72 5 months ago
R/S is coming … money down the drain
👍️0
Monksdream Monksdream 5 months ago
AGEN new 52 week low
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 6 months ago
$AGEN
https://x.com/hannahadad8890/status/1741101133777486197?s=61
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 6 months ago
$AGEN
https://x.com/hannahadad8890/status/1739966219229258048?s=61
👍️0
Doktornolittle Doktornolittle 7 months ago
Admin(s) please erase my post # 1170. I don't think the issues were the fault of B. Riley or ASCO... . Maybe, but it is unclear and not worth having the negativity there for posterity.
👍️0
Monksdream Monksdream 8 months ago
AGEN new 52 week low
👍️0
Monksdream Monksdream 8 months ago
AGEN new 52 week low
👍️0
Monksdream Monksdream 9 months ago
AGEN new 52 week low

👍️0
Monksdream Monksdream 9 months ago
AGEN new 52 week low
👍️0
Doktornolittle Doktornolittle 1 year ago
... B.Riley psswd is in immediate registration confirmation email. That may not be unusual, but the email subject line gives no indication that it contains a psswd. It gives a warm and fuzzy that your registration did go through, so the reader is not compelled to open the email. The reader already knows they registered and the reader does not yet know that they are going to have to login with a password. May be the usual way to do this, but I don't think it is a good way.

As for ASCO GI. Some say the abstracts were embargoed since late-breaking. Maybe so, but why then did the ASCO website instruct me to login to view the abstract. This is with the abstract already located. This is on the abstract page, which only contains the header at that point. Causes confusion.
👍️0
Doktornolittle Doktornolittle 1 year ago
B Riley would not allow me to view the recent webcast. ASCO would not allow me to view the recently "released: Abstracts. No PR from the company. This while Yhoo Finance is so controlled and filtered since the recent takeover that no light escapes there either.

If you had a similar experience, please message me and we can join forces for a complaint to the SEC.

More detail:
B Riley has no contact other than their private email system which does not work.
ASCO: Found the abstracts, but they told me that I had to log in to view the abstract beyond the header and authors. I spent 12 hours trying to do that. After many dead end phone calls and emails, I finally got them to allow me to log in. Went back to the abstract and now they tell me, you don't have access to the abstract. A slightly different message than when I was not logged in, but still no access.

I videotaped my efforts to access the webcast and abstracts. I suggest you do the same if you have problems like this in the future.

These are SEC violations.

Where is the SEC on these things? I suspect they could care less, but I want to find out.
👍️0
Doktornolittle Doktornolittle 2 years ago
SITC Oral Presentation on BOT w/wo BAL tomorrow with about a thousand authors. It is a brief presentation, but there are only 4 such on schedule and they are the last notes of the entire SITC session. It is likely that everybody at SITC who can get to these final presentations will be there. I am no technical expert in these matters, but I am confident that BOT is a big deal for a couple of reasons beyond the data. 1) In a brief presentation after ASCO, there were major league Cancer experts discussing the presented results. Those experts were truly impressed with this activity against cold tumors. I have seen phony looking presentations by small biotech companies, and this was not that. Of that I am certain and will listen to nobody else's opinion about it. 2) Agenus has been touting BOT for years now. They knew from the beginning that they had something very special. For me it is not a great leap of faith to expect big things from BOT w/wo BAL. No posts here in almost a year. None for months at alter forum IV, and alter other forum just went through a huge change. Suddenly no new posts in the last 24 hours in the middle of SITC? I don't thinks so. So far, I give the facelift at hooya a big thumbs down. This is it guys. Your new home.
👍️ 1
stockguard stockguard 3 years ago
AGEN Agenus initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Michael King initiated coverage of Agenus with a Buy rating and $12 price target. The company has developed a broad portfolio of promising antibodies and bispecifics covering many validated targets in immuno-oncology, King tells investors in a research note. The company has "struck multiple lucrative development agreements with some of the industry's leading oncology players," adds the analyst.
👍️0
north40000 north40000 3 years ago
$11 from $12. Buy rating. Analyst has been switching back and forth between $11 and $12. November date on last PT, per GOOGL search.
👍️0
investtemp investtemp 3 years ago
what was the B Riley target price?
👍️0
stockguard stockguard 3 years ago
B. Riley bullish on Novavax, Agenus amid Omicron spread.
B. Riley analyst Mayank Mamtani reiterates his sector-level view of the need for at least annual vaccine boosters and there being a durable COVID vaccine market, sharing many of the attributes with an expanding flu market that has been clearly rewarding differentiated vaccine solutions. The analyst views sustenance of multiple vaccine modalities prevailing over an "mRNA takes all" viewpoint. Mamtani has a Buy rating and a price target of $305 on Novavax (NVAX) as Omicron variant-specific development preparedness and COV-Boost data reiterate robust positioning in global, durable COVID-19, and flu markets. The analyst also has a Buy rating and a price target on Agenus (AGEN) as he believes under-the-radar SaponiQx's adjuvant is poised to play a meaningful role in strong expected protein subunit vaccine demand. He keeps a Neutral rating on Vaxart (VXRT), calling it one of the few "investable" COVID-19 vaccine pipeline programs directly tackling the transmission issue.
👍️0
stockguard stockguard 3 years ago
New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
https://finance.yahoo.com/news/agenus-subsidiary-saponiqx-builds-innovative-113000784.html
👍️0
stockguard stockguard 3 years ago
Will not be in the money until it hits their price, no biggie on this small fry:
SEC Form S-3ASR filed by Agenus Inc.
https://quantisnow.com/insight/2002956?s=s



👍️0
pipette pipette 3 years ago
There was an article in Oct 26 did u get that one? Most trading platforms have news with their tickers too.
👍️0
malice1 malice1 3 years ago
China just shut down yahoo and aol. I was on the Yahoo Agen Board. Can anyone keep me updated on any significant news?
👍️0
Jnk Jnk 3 years ago
Got it!
👍️0
stockguard stockguard 3 years ago
Either way i`m only focusing on 1181 now and the cash they have on the books to see it through. Market was overly fixated on Bali in cervical which was small niche as even Management suggested.
👍️0
Jnk Jnk 3 years ago
Well I just bought a bunch more shares!! Hope it pays out!!
👍️0
stockguard stockguard 3 years ago
UPDATE: Agenus withdraws cervical cancer application, and a behind the scenes David vs. Big Pharma regulatory battle is revealed
https://www.fiercebiotech.com/biotech/agenus-withdraws-cervical-cancer-application-for-balstilimab-after-fda-fully-authorizes
👍️0
stockguard stockguard 3 years ago
Agenus calls out FDA for playing favorites with Merck, pulls cervical cancer BLA at agency's request
https://endpts.com/agenus-calls-out-fda-for-playing-favorites-as-it-pulls-cervical-cancer-bla-at-agencys-request/
👍️0
malice1 malice1 3 years ago
longboarder have any idea what happened the last two days?
👍️0
longboarder7892 longboarder7892 3 years ago
Thank you Dr. Hidalgo for all that you have done here with AGEN in just a few months we went from 2.50 to almost 6.50 and will be helping save lives. I hope your work will do the same for my other company that you are on the board of and the PI of their trial. AGEN is looking great with the BMY investment... mmmm

Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
Bristol-Myers Squibb Company (NYSE:BMY) and Agenus Inc. (NASDAQ:AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus' proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies this approach has shown significant potential in tumor models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are ineffective.
👍️0
conix conix 3 years ago
AGEN Chart

👍️0
ClayTrader ClayTrader 3 years ago
* * $AGEN Video Chart 05-18-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
JohnLocke101 JohnLocke101 3 years ago
Bristol Myers bets big on anti-TIGIT bispecific from Agenus in a partnership worth $1.5B+
👍️0
iancnyc iancnyc 3 years ago
thank god i heard on
look at that!!!
👍️0
moonurneighbor moonurneighbor 3 years ago
Great news!
👍️0
JohnLocke101 JohnLocke101 3 years ago
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
👍️0
iancnyc iancnyc 3 years ago
what’s going on with this Turd today?
👍️0
stockguard stockguard 3 years ago
Agenus 1181 New Cancer Response Data Adds To Conviction
https://seekingalpha.com/article/4419058-agenus-1181-new-cancer-response-data-adds-to-conviction
👍️0
stockguard stockguard 3 years ago
Agenus Inc. (NASDAQ: AGEN) reported earlier this year that it has entered into a clinical collaboration with Nelum Corp. to evaluate the safety and efficacy of zalifrelimab, Agenus' anti-CTLA-4 antibody, in combination with NLM-001, Nelum's small molecule hedgehog inhibitor, and chemotherapy for first-line advanced pancreatic cancer. "This collaboration with Nelum is an exciting next step in our partnership strategy to broaden combinations and indications with our late-stage checkpoint antibodies," said Julie DeSander, Vice President of Business Development and Alliance Management. "Zalifrelimab, our first generation anti-CTLA-4 antibody, shows promising results alone and in combination with balstilimab, our anti-PD-1 antibody, and offers the potential to expand therapeutic benefit in novel combinations."
👍️0
stockguard stockguard 3 years ago
May hear further strong points from the presentation.
Agenus to Present New Clinical Data on AGEN1181 at AACR 2021
https://www.globenewswire.com/fr/news-release/2021/03/10/2190840/0/en/Agenus-to-Present-New-Clinical-Data-on-AGEN1181-at-AACR-2021.html
👍️0
moonurneighbor moonurneighbor 3 years ago
“These are very exciting results which demonstrate the potential of AGEN1181 as an efficacious next-generation CTLA-4 antibody. AGEN1181 is showing activity in difficult-to-treat tumors without the neuroendocrine or significant liver toxicities commonly observed with the currently-approved CTLA-4 antibody ipilimumab,” said Dr. Steven O’Day, Chief Medical Officer
👍️0
MDizzle MDizzle 3 years ago
Agenus Announces New Responses for AGEN1181





Agenus Announces New Responses for AGEN1181
-- 6 total confirmed objective clinical responses in colon, ovarian, and
endometrial cancers

-- No complement-mediated toxicities reported

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced additional confirmed objective clinical responses from its Phase 1/2 trial of AGEN1181, its next-generation anti-CTLA-4, as monotherapy and in combination with Agenus' anti-PD-1 balstilimab.

"These are very exciting results which demonstrate the potential of AGEN1181 as an efficacious next-generation CTLA-4 antibody. AGEN1181 is showing activity in difficult-to-treat tumors without the neuroendocrine or significant liver toxicities commonly observed with the currently-approved CTLA-4 antibody ipilimumab," said Dr. Steven O'Day, Chief Medical Officer at Agenus. "The responses seen in patients with ovarian and MSS colorectal cancer are particularly encouraging given the generally low activity seen with immunotherapy in these indications."

The Phase 1 dose escalation trial has had no reports of complement-mediated toxicities. These are severe toxicities associated with first-generation CTLA-4 antibodies. The trial has also defined the optimal combination dose for AGEN1181 +/- balstilimab.

Agenus also presented on the first-ever report of intratumoral Treg depletion with a CTLA-4 antibody in clinical trials at SITC 2020.

The summary of responses with AGEN1181 alone or in combination with balstilimab are as follows:(1)
-- CR in PD-L1(-) MSS endometrial cancer patient (1181 monotherapy)

-- CR by PET in PD-L1(-) MSS endometrial cancer patient (1181 + bal)

-- PR in PD-L1(-) refractory ovarian cancer patient (1181 + bal)

-- PR in colorectal cancer patient (1181 + bal)

-- PR in MSS colorectal cancer patient (1181 + bal) -- new confirmed
response

-- PR in ovarian cancer patient (1181 + bal) -- new confirmed response

AGEN1181 alone and in combination with balstilimab has expanded dosing into colorectal cancer. Phase 2 trials in additional cancer indications are scheduled to commence shortly.

👍️0
moonurneighbor moonurneighbor 3 years ago
Awesome!
https://investor.agenusbio.com/news-releases/news-release-details/agenus-announces-new-responses-agen1181
👍️0

Your Recent History

Delayed Upgrade Clock